Edesa Biotech, Inc.

Equities

EDSA

CA27966L3065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-17 pm EDT			5-day change	1st Jan Change
4.4 ^USD	+1.25%		-6.08%	-3.72%

Mar. 05	Top Premarket Gainers	MT
Feb. 09	Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021

December 28, 2021 at 04:57 pm EST

Edesa Biotech, Inc. reported earnings results for the full year ended September 30, 2021. For the full year, the company reported net loss was USD 13.34 million compared to USD 6.36 million a year ago. Basic loss per share from continuing operations was USD 1.1 compared to USD 0.74 a year ago.

Latest news about Edesa Biotech, Inc.

Top Premarket Gainers	Mar. 05	MT
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 09	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 15	CI
Top Premarket Decliners	Dec. 13	MT
HC Wainwright Adjusts Price Target on Edesa Biotech to $21 From $70, Keeps Buy Rating	Nov. 29	MT
Top Premarket Gainers	Nov. 22	MT
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	Nov. 20	CI
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	23-10-25	CI
Top Premarket Decliners	23-10-13	MT
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12	MT
Sector Update: Health Care	23-10-12	MT
Top Midday Gainers	23-10-12	MT
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	23-10-12	CI
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	23-10-10	MT
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	23-09-28	CI
HC Wainwright Adjusts Edesa Biotech Price Target to $10 From $16, Maintains Buy Rating	23-08-15	MT
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-09	CI
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	23-06-28	CI
Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023	23-06-27	CI
Edesa Biotech, Inc. Approves Resignation of Kathi Niffenegger as Chief Financial Officer	23-05-24	CI
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11	CI
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	23-03-16	CI
Edesa Biotech, US FDA Agree on EB05 Phase 3 Trial's Primary Endpoint, Population	23-03-15	MT
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study	23-03-15	CI
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-10	CI

Chart Edesa Biotech, Inc.

Duration

Period

More charts

Company Profile

Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Companyâs advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - LSX World Congress

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.4 USD

Average target price

24 USD

Spread / Average Target

+445.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
EDESA BIOTECH, INC.	-3.72%	13.78M
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.09B
ARGENX SE	-1.02%	22.05B
BIONTECH SE	-18.14%	20.81B
GENMAB A/S	-6.87%	19.06B
WUXI APPTEC CO., LTD.	-40.70%	16.05B
BEIGENE, LTD.	-26.89%	14.01B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.38B
SAREPTA THERAPEUTICS, INC.	+22.25%	11.01B

Bio Therapeutic Drugs